Original
Outcomes of Three Intravitreal Injections of Bevacizumab for Diabetic Macular Oedema
Chowdhury MK,1 Islam MS,2 Marzana MA,3 Sultana N,4, Das T,5 *Nurunnabi M6
- Dr. Md. Kamrul Islam Chowdhury, Assistant Professor, Department of Ophthalmology, Jalalabad Ragib-Rabeya Medical College and Hospital, Sylhet, Bangladesh. kisight@gmail.com. ORCID:https://orcid.org/0009-0005-7140-2917
- Dr. Md.Shirajul Islam, Associate Professor, Department of Retina, Gopalganj Eye Hospital and Training Institute, Gopalganj.
- Dr. Must. Ayesha Marzana, Assistant Professor, Department of Gynecology and Obstetrics, Jalalabad Ragib-Rabeya Medical College and Hospital, Sylhet, Bangladesh.
- Dr. Naima Sultana, Medical Officer, Department of Neuromedicine, Sylhet Women’s Medical College Hospital, Sylhet, Bangladesh.
- Dr. Tirtho Das, Medical Officer, Department of Ophthalmology, Jalalabad Ragib-Rabeya Medical College and Hospital, Sylhet, Bangladesh.
- *Dr. Mohammad Nurunnabi, Assistant Professor, Department of Community Medicine and Public Health, Sylhet Women’s Medical College, Sylhet, Bangladesh. nur.somch@gmail.com. ORCiD: https://orcid.org/0000-0001-9472-9369
*For correspondence
Abstract
Background: Diabetic macular oedema (DMO) is a leading cause of visual impairment among patients with diabetic retinopathy. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy, particularly Bevacizumab, is widely used to reduce macular oedema and improve visual outcomes.
Objective: To evaluate the visual and anatomical outcomes following three monthly intravitreal injections of Bevacizumab in patients with diabetic macular oedema.
Methods: This hospital-based cross-sectional study was conducted in the Department of Ophthalmology, Gopalganj Eye Hospital and Training Institute, from July 2022 to December 2023. A total of 102 patients (150 eyes) with type 2 diabetes mellitus and centre-involving DMO were included. Eligible eyes received three monthly intravitreal injections of Bevacizumab (1.25 mg/0.05 mL). Best corrected visual acuity (BCVA), central foveal thickness (CFT) measured by spectral domain optical coherence tomography, and intraocular pressure (IOP) were assessed at baseline and one month after the final injection.
Results: The mean BCVA improved significantly from 0.82 ± 0.41 logMAR at baseline to 0.55±0.39 logMAR after treatment (p<0.001). The mean CFT decreased from 441.20 ± 148.60 μm to 358.62±142.41 μm (p<0.001). A total of 96.6% of treated eyes showed visual improvement, with 41.3% gaining two or more lines of vision. The most common complication was subconjunctival haemorrhage (21.3%), while serious adverse events such as retinal detachment and endophthalmitis were rare (2.7% each).
Conclusion: Three monthly intravitreal Bevacizumab injections significantly improve both visual acuity and macular thickness in patients with diabetic macular oedema, with an acceptable safety profile.
[Shaheed Syed Nazrul Islam Med Col J 2026, July; 11 (2):242-250]
DOI: https://www.doi.org/10.69699/ssnimcj.2026.11.2.18